Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Status:
Active, not recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of
ME-401 in the treatment of Japanese participants with Relapsed or Refractory indolent B-Cell
Non-Hodgkin's Lymphoma